The future of heart disease treatment is bold

Tenaya is using biological insights from our team and our collaborators to discover novel therapies for various forms of heart disease, the leading cause of mortality worldwide. We are advancing a pipeline of disease-modifying therapies developed using our product platforms and core internal capabilities to target defined sub-populations of patients with rare or highly prevalent forms of heart disease. As displayed below, each of our product platforms is designed to address different problems that have historically plagued the development of novel therapies for heart disease.

PRECISION MEDICINE

Our Precision Medicine platform uses human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as proprietary disease models and analysis of human genetics for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on efficacy in animal models to develop therapies intended for human heart disease. We believe this platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner—including gene therapy, small molecules, and biologics—for both genetic and non-genetic forms of heart disease.

GENE THERAPY

Our Gene Therapy platform uses AAVs to deliver genes to specific cells in the heart to correct or compensate for functional defects. We have the ability to use both known AAV capsids as well as novel capsids identified through our internal capsid engineering capabilities to target cardiomyocytes, cardiac fibroblasts  or other cells important to the proper functioning of the heart. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the underlying problems that contribute to heart disease. We believe this platform has potentially broad utility for both genetic and non-genetic forms of heart disease.

CELLULAR REGENERATION

Our Cellular Regeneration platform uses viral vectors to deliver genes to specific cells in the heart to regenerate cardiomyocytes in vivo. The product candidates arising from this platform are intended to overcome the shortcomings of traditional therapies that are not able to address the loss of cardiomyocytes. We believe this platform has potentially broad utility across a range of heart conditions that result in the loss of cardiomyocytes, including myocardial infarction, chemotherapy-related toxicity, and viral infection.

Looking to collaborate? Interested in new career opportunities at Tenaya?
Want to know more?

CONTACT US